How Hulio® works

Hulio® is a recombinant human monoclonal antibody that helps to reduce the symptoms of immune-mediated diseases in children and adult population, such as moderate-to-severe active rheumatoid arthritis (RA), moderate-to-severe chronic plaque psoriasis (Pso) and inflammatory bowel disease (IBD: Crohn’s disease and ulcerative colitis).

Immune-mediated diseases reflect an imbalance between effector and regulatory immune responses, typically developing through stages of initiation and propagation, and often showing phases of resolution (indicated by clinical remissions) and exacerbations (indicated by symptomatic flares). These diseases are significant due to their chronic nature, the associated healthcare cost and their prevalence in young populations during the prime phase of their working and peak reproductive years. Current therapies, such as (tumour necrosis factor-alpha) TNF-α antagonists have changed the course of the disease.1 As a biosimilar, Hulio® inhibits TNF-α, thereby reducing inflammation and other disease symptoms.2

Hulio® works for Chronic Inflammatory Diseases

Hulio® acts on chronic inflammatory diseases in adults, such as rheumatoid arthritis, psoriatic arthritis, psoriasis, Crohn’s disease and ulcerative colitis. It also acts on paediatric inflammatory diseases. Hulio® is specially developed to treat immune-mediated conditions.3 It aids in controlling the existing symptoms of the immune-mediated diseases and in reducing the future risks. The healthcare professionals should guide the patients on how to use Hulio®.

Mechanism of Action

Pro-inflammatory cytokines can mediate increased skin proliferation, T-cell activation, cell infiltration and angiogenesis. Binding of adalimumab (Hulio®) to TNF-α prevents the interaction of TNF-α with its receptors, thereby reducing the inflammation.4

Restricted access

The website you are trying to access is designed for healthcare professionals only - the content is not designed for the general public.

Are you a healthcare professional based in UK or Ireland?

YES
NO

Report side effects

▼This medicine is subject to additional monitoring. This will allow quick identification of new safety information. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare providers are asked to report any suspected adverse reactions. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. In order to support effective tracking and traceability of biologics including biosimilars, it is recommended that the brand name and batch number are recorded and used when reporting adverse events.

You are now leaving the Hulio® uk website